CA3005997A1 - Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor - Google Patents

Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor Download PDF

Info

Publication number
CA3005997A1
CA3005997A1 CA3005997A CA3005997A CA3005997A1 CA 3005997 A1 CA3005997 A1 CA 3005997A1 CA 3005997 A CA3005997 A CA 3005997A CA 3005997 A CA3005997 A CA 3005997A CA 3005997 A1 CA3005997 A1 CA 3005997A1
Authority
CA
Canada
Prior art keywords
cancer
fucose
deoxy
fluoro
checkpoint inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3005997A
Other languages
English (en)
French (fr)
Inventor
Shyra Gardai
Che-Leung Law
Peter Senter
Nicole OKELEY
Jessica FIELD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of CA3005997A1 publication Critical patent/CA3005997A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3005997A 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor Abandoned CA3005997A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562263228P 2015-12-04 2015-12-04
US62/263,228 2015-12-04
US201662308583P 2016-03-15 2016-03-15
US62/308,583 2016-03-15
US201662321857P 2016-04-13 2016-04-13
US62/321,857 2016-04-13
PCT/US2016/064783 WO2017096274A1 (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Publications (1)

Publication Number Publication Date
CA3005997A1 true CA3005997A1 (en) 2017-06-08

Family

ID=58797961

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3005997A Abandoned CA3005997A1 (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Country Status (13)

Country Link
US (1) US20180353524A1 (enExample)
EP (1) EP3383404A4 (enExample)
JP (1) JP6906520B2 (enExample)
KR (1) KR20180086233A (enExample)
CN (1) CN108289903B (enExample)
AU (1) AU2016362993A1 (enExample)
BR (1) BR112018011261A2 (enExample)
CA (1) CA3005997A1 (enExample)
EA (1) EA201891340A1 (enExample)
IL (1) IL259479B (enExample)
MX (1) MX385283B (enExample)
SG (2) SG11201804263PA (enExample)
WO (1) WO2017096274A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019165A2 (en) 2010-08-05 2012-02-09 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
IL271012B2 (en) * 2017-06-07 2023-12-01 Seagen Inc T cells with reduced surface fucosylation and methods for their preparation and use
WO2019075449A1 (en) * 2017-10-13 2019-04-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. FUCOSYLATION AND IMMUNOSURVEILLANCE OF MELANOMA
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
JP2022514299A (ja) * 2018-12-19 2022-02-10 シージェン インコーポレイテッド 抗体の制御されたフコシル化
WO2021034774A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN111973749B (zh) * 2020-09-07 2023-03-21 威海人生药业集团股份有限公司 一种抗肿瘤免疫治疗的药物组合物
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN113274502B (zh) * 2021-05-05 2023-01-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于特定型三阴乳腺癌免疫治疗的组合物
US20240238318A1 (en) * 2021-05-06 2024-07-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. L-fucose and anti-androgen receptor therapy for treatment of cancer
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
CN115466297B (zh) * 2022-08-25 2023-07-07 青岛农业大学 L-岩藻糖的应用以及动物饲料
WO2024077106A2 (en) * 2022-10-04 2024-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Leveraging l-fucose-mediated signaling to induce monocyte-derived dendritic cell polarization
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019165A2 (en) * 2010-08-05 2012-02-09 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물

Also Published As

Publication number Publication date
JP6906520B2 (ja) 2021-07-21
MX2018006674A (es) 2018-11-09
IL259479B (en) 2022-03-01
EA201891340A1 (ru) 2018-11-30
MX385283B (es) 2025-03-18
KR20180086233A (ko) 2018-07-30
CN108289903A (zh) 2018-07-17
WO2017096274A1 (en) 2017-06-08
BR112018011261A2 (pt) 2018-11-21
US20180353524A1 (en) 2018-12-13
SG11201804263PA (en) 2018-06-28
EP3383404A4 (en) 2019-07-31
IL259479A (en) 2018-07-31
JP2019501145A (ja) 2019-01-17
CN108289903B (zh) 2021-08-03
AU2016362993A1 (en) 2018-07-12
SG10202005298RA (en) 2020-07-29
EP3383404A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
US20180353524A1 (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
US20240000928A1 (en) Approach for treatment of cancer via immunomodulation by using talabostat
US20230414540A1 (en) Combination of immunotherapy with local chemotherapy for the treatment of malignancies
JP7360418B2 (ja) 腫瘍内微小環境に影響を与えるベータ－グルカン方法と組成物
BR112021002826A2 (pt) construtos de receptor de célula t e usos dos mesmos
EP3132802B1 (en) Therapeutic agent for solid cancer
US20250213689A1 (en) Immunogenic composition for the treatment of cancer
KR20240110996A (ko) 면역 관문 저해제와 조합한 플리나불린의 용도
JP2021020921A (ja) 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
TW202241468A (zh) 用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
JP2022512161A (ja) 免疫療法のための組成物及び方法
AU2019287765A1 (en) Increasing immune activity through modulation of postcellular signaling factors
EP3468559A1 (en) Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors
CN113316449A (zh) 胍那苄作为免疫疗法的佐剂
CA3143135A1 (en) Combination cancer immunotherapy
Lee et al. Venlafaxine inhibits the development and differentiation of dendritic cells through the regulation of P-glycoprotein
KR102352127B1 (ko) Mitf 억제제를 유효성분으로 함유하는 골수-유래 억제세포 저해용 조성물
EP3630126A1 (en) Ceramide nanoliposomes, compositions and methods of using for immunotherapy
TW202300014A (zh) 腫瘤儲存及細胞培養組成物
WO2022192268A1 (en) Methods of enhancing antibody therapies
WO2014159923A1 (en) Enhancement of vaccines
JP2021517172A (ja) 活性成分としてｌｒｉｔ２阻害剤を含む、がんを予防又は治療するための医薬組成物

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230223

FZDE Discontinued

Effective date: 20230223